Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for varmints passing through the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is strawberry cream. As always, you are invited to join us. The neurons could use all the help they can get. Meanwhile, here is the latest menu of tidbits for you to digest as you embark on your journey, which we hope is satisfying and rewarding. On that note, time to get cracking. Best of luck, and do keep in touch. …
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing it closer to joining the highly competitive GLP-1 drug market, STAT tells us. The biotech previously said it anticipated starting a Phase 2b trial after getting positive results from a Phase 2 study. But after receiving feedback from regulators, the company now plans to move directly into a Phase 3 trial. The drug so far has been tested as a weekly injection, but based on pharmacokinetics data, Viking now also intends to explore monthly dosing in a future study. The developments move Viking ahead in the race among dozens of biotechs to bring a drug onto the lucrative obesity market.
A U.S. appeals court ruled 3-to-0 that Idaho and a group of GOP-led states will not be allowed to join a lawsuit filed by the state of Washington against a U.S. Food and Drug Administration regulation on mifepristone, The Hill writes. The 9th Circuit Court of Appeals said Idaho failed to prove an injury related to the regulations, so it did not have standing to challenge, and as a result could not intervene. The court said it was “guided by the Supreme Court’s recent decision on standing” in a case filed by the Alliance for Hippocratic Medicine, a group of anti-abortion doctors, which was similarly dismissed because they could not prove they were harmed by use of the medication.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect